Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
358
LIM ET AL
359
RESULTS
Incidence. Using the 4 ACR criteria definition.
In 20022004, a total of 267 cases fulfilled 4 ACR
criteria for SLE, including 196 black patients, 62 white
patients, and 9 patients of other racial groups (Table 1).
The overall crude and age-adjusted incidence rates
were similar (5.6 per 100,000 person-years). Ageadjusted incidence rates were 5 times higher among
women than men (9.2 [95% CI 8.1, 10.5] versus 1.8 [95%
CI 1.3, 2.4]). Among women, the age-adjusted rates in
black persons were nearly 3 times higher than those in
white persons (13.4 versus 4.7); among men, the rates
in black persons were 4 times higher than those in
white persons (3.2 versus 0.7). C-RC analysis estimated
that there were 31 (95% CI 18, 55) missed cases of SLE,
resulting in a higher C-RC adjusted rate of 6.3 per
100,000 person-years.
Overall age-specific incidence rates were significantly different between black and white persons, both
360
LIM ET AL
Table 1. Incidence of SLE in Fulton and DeKalb counties in Georgia, January 1, 2002 through December 31, 2004, according to 2 analytical case
definitions, categorized by race and sex*
4 ACR criteria
Capturerecapture
Race/
ethnicity,
sex
Overall
Women
Men
Black
Women
Men
White
Women
Men
Catchment
area
population
No. of
(person-years) cases
4,742,264
2,424,592
2,317,672
2,321,302
1,239,819
1,081,483
2,210,389
1,082,131
1,128,258
267
228
39
196
168
28
62
53
9
Crude rate
(95% CI)
Age-adjusted
rate (95% CI)
No. of cases
missed
(95% CI)
Capture
recapture
adjusted rate
(95% CI)
No. of
cases
31 (18, 55)
28 (15, 51)
4 (1, 17)
22 (11, 43)
20 (10, 42)
3 (1, 10)
8 (2, 23)
5 (1, 22)
1 (0, 16)
345
300
45
252
221
31
79
68
11
Age-adjusted
rate (95% CI)
* Rates are per 100,000 person-years (95% confidence intervals [95% CIs]). Age-adjusted rates used the 2000 projected US population.
The combined case definition for systemic lupus erythematosus (SLE) consisted of the following 3 criteria: 4 American College of Rheumatology
(ACR) criteria; 3 ACR criteria plus a final diagnosis of SLE rendered by a rheumatologist; or 4 ACR criteria and either biopsy findings consistent
with World Health Organization class IIVI lupus nephritis or end-stage renal disease secondary to SLE that required dialysis/renal transplantation.
Values are the estimated number of SLE cases that were missed and the capturerecaptureadjusted incidence rate.
Using the combined case definition, the ageadjusted rate in women was 6 times higher than that in
men (11.7 versus 1.9 per 100,000 person-years). The
age-adjusted rate in black patients was 3.2 times higher
than that in white patients (10.7 versus 3.3 per 100,000
person-years). The proportions were different when
comparing sex by race. The rate in women was 2.9 times
higher in black patients than in white patients (17.0
versus 5.8 per 100,000 person-years). Black men had a
4.3 times higher incidence rate compared with white
men (3.4 versus 0.8 per 100,000 person-years).
Prevalence. Using the 4 ACR criteria definition.
In 2002, a total of 1,156 persons fulfilled 4 ACR
criteria for SLE, including 889 black patients, 251 white
patients, and 16 patients of other races (Table 2). The
overall crude prevalence rate was 74.4 (95% CI 70.3,
78.9) per 100,000 person-years. Age-adjusted prevalence
rates were similar to the crude rates. The age-adjusted
prevalence rate in women was nearly 9 times higher than
that in men (127.6 versus 14.7). Among women, the
prevalence rate in black patients was 3 times higher
than that in white patients (196.2 versus 59.0); among
men, the prevalence rate in black patients was 3 times
higher than that in white patients (23.7 versus 7.5).
C-RC analysis was done only for the 4 ACR
criteria case definition and yielded an estimated 133
(95% CI 98, 181) missing SLE cases, resulting in a
361
Figure 2. Age-specific incidence and prevalence rates of systemic lupus erythematosus, according to a case definition of 4 American College of
Rheumatology criteria, by sex and race, in Fulton and DeKalb Counties, Georgia, 20022004. Bars show the 95% confidence intervals.
1,552,970
794,310
758,660
765,475
408,642
356,833
720,292
352,914
367,378
Race/
ethnicity,
sex
Overall
Women
Men
Black
Women
Men
White
Women
Men
1,156
1,043
113
889
806
83
251
222
29
No. of
cases
74.4 (70.3, 78.9)
131.3 (123.6, 139.5)
14.9 (12.4, 17.9)
116.1 (108.8, 124.0)
197.2 (184.1, 211.3)
23.3 (18.8, 28.8)
34.8 (30.8, 39.4)
62.9 (55.2, 71.7)
7.9 (5.5, 11.3)
Crude rate
(95% CI)
73.0 (68.9, 77.4)
127.6 (120, 135.7)
14.7 (12.2, 17.6)
118.5 (111.1, 126.5)
196.2 (183, 210.2)
23.7 (19.1, 29.3)
32.7 (28.8, 37.2)
59.0 (51.5, 67.5)
7.5 (5.2, 10.9)
Age-adjusted rate
(95% CI)
133 (98, 181)
115 (83, 159)
20 (8, 49)
91 (64, 131)
79 (54, 115)
13 (4, 42)
36 (18, 73)
33 (15, 74)
4 (0, 19)
No. of cases
missed
(95% CI)
83.0 (78.6, 87.7)
145.8 (137.6, 154.4)
17.5 (14.8, 20.8)
128.0 (120.3, 136.3)
216.6 (202.8, 231.3)
26.9 (22, 32.8)
39.8 (35.5, 44.7)
72.3 (63.9, 81.7)
9.0 (6.4, 12.6)
Capturerecapture
adjusted rate
(95% CI)
Capturerecapture
1,446
1,300
146
1,094
985
109
328
292
36
No. of
cases
Crude rate
(95% CI)
Age-adjusted rate
(95% CI)
* Rates are per 100,000 person-years (95% confidence intervals [95% CIs]). Age-adjusted rates used the 2000 projected US population.
The combined case definition for systemic lupus erythematosus (SLE) consisted of the following 3 criteria: 4 American College of Rheumatology (ACR) criteria; 3 ACR
criteria plus a final diagnosis of SLE rendered by a rheumatologist; or 4 ACR criteria and either biopsy findings consistent with World Health Organization class IIVI lupus
nephritis or end-stage renal disease secondary to SLE that required dialysis/renal transplantation.
Values are the estimated number of SLE cases that were missed and the capturerecaptureadjusted incidence rate.
Catchment
area
population
(person-years)
4 ACR criteria
Table 2. Prevalence of SLE in Fulton and DeKalb counties in Georgia, January 1, 2002 through December 31, 2002, according to 2 analytical case definitions, categorized by
race and sex*
362
LIM ET AL
363
Table 3. Clinical manifestations of SLE among the incident and prevalent cases, January 1, 2002 through December 31, 2004, categorized by race*
4 ACR criteria plus ESRD
No. (%) of incident cases
Clinical
manifestation
Overall
(n 267)
Black
patients
(n 196)
White
patients
(n 62)
Subgroup
difference
(95% CI)
Overall
(n 1,156)
Black
patients
(n 889)
White
patients
(n 251)
Subgroup
difference
(95% CI)
Malar rash
Discoid rash
Photosensitivity
Oral ulcers
Arthritis
Serositis
Renal disorder
ESRD
Neurologic disorder
Hematologic disorder
Immunologic disorder
Antinuclear antibody
55 (20.6)
40 (15.0)
43 (16.1)
61 (22.8)
167 (62.5)
91 (34.1)
91 (34.1)
5 (1.9)
24 (9.0)
216 (80.9)
187 (70.0)
244 (91.4)
38 (19.4)
32 (16.3)
25 (12.8)
42 (21.4)
122 (62.2)
74 (37.8)
75 (38.3)
4 (2)
18 (9.2)
160 (81.6)
143 (73)
180 (91.8)
12 (19.4)
7 (11.3)
17 (27.4)
18 (29)
38 (61.3)
15 (24.2)
12 (19.4)
1 (1.6)
6 (9.7)
49 (79)
38 (61.3)
56 (90.3)
374 (32.4)
262 (22.7)
295 (25.5)
250 (21.6)
779 (67.4)
491 (42.5)
394 (34.1)
78 (6.7)
156 (13.5)
870 (75.3)
736 (63.7)
949 (82.1)
272 (30.6)
225 (25.3)
199 (22.4)
175 (19.7)
600 (67.5)
386 (43.4)
326 (36.7)
75 (8.4)
126 (14.2)
672 (75.6)
584 (65.7)
738 (83)
93 (37.1)
37 (14.7)
92 (36.7)
73 (29.1)
169 (67.3)
100 (39.8)
60 (23.9)
3 (1.2)
29 (11.6)
184 (73.3)
139 (55.4)
199 (79.3)
* Clinical manifestations consisted of the 11 American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) plus
end-stage renal disease (ESRD; defined by abstraction and the US Renal Data System database). For incident cases, manifestations were counted
through the first year after diagnosis. For prevalent cases, manifestations were counted through December 31, 2002. 95% CI 95% confidence
interval.
19651973, San
Francisco, CA, US
(27)
19701977, Baltimore,
MD, US (28)
19801990, island of
Curacao, The
Netherlands Antilles
(29)
19851990, Allegheny
County, PA, US
(15)
19501992, Rochester,
MN, US (30)
1,100,000 (NAN
and NANN)
381,427 (mostly
African Caribbean)
19801996, province
of Manitoba,
Canada (31)
19901999, island of
Martinique, French
West Indies (33)
2000, NHANES-III,
US population
sample (34)
29,885 (1950)70,745
(1990) (94% white)
Population at risk
(race/ethnicity)
Self-reported
physician diagnosis
with/without SLE
drugs
4 ACR 1982
criteria (definite)
or 3 ACR criteria
(probable) by chart
review and
examination
4 ACR 1982
criteria by
investigator chart
review
4 ACR 1982
criteria validated
by chart review
4 ACR criteria
validated by chart
review
4 ACR 1982
criteria by review
of 430 medical
records
Clinical suspicion,
characteristic
serologic and
pathologic findings
4 ACR 1971
criteria by chart
review
4 ACR 1971
criteria by chart
review
4 ACR 1982
criteria by chart
review
Case definition
Community diagnostic
retrieval system (SLE,
ANA, LE cell, falsepositive serologic test for
syphilis)
Regional arthritis center
database and medical
records of all
rheumatologists,
hematologists,
nephrologists, and general
internists
Community referrals to
lupus evaluation center,
practice database search
(SLE)
40 by self-report, 12
taking SLE drugs
286 total
48 total
ND
4.7 overall
ND
2.07.4 in NAN,
0.92.3 in
NANN
3.1 overall,
5.6 in 1980
1992, 1.5 in
19501979
2.4 overall
4.6 overall
7.6 overall
2.0 overall
Incidence, per
100,000 per year
74 total
Population-based studies of the incidence and prevalence of SLE in North America, including the Caribbean and Puerto Rico*
Table 4.
241 by self-report,
54 taking SLE
drugs
64.2 overall
94 overall
122 in January
1992
ND
48 overall, 84 in
females, 9 in
males
ND
51 overall
19 overall
Prevalence,
per 100,000
364
LIM ET AL
268,792 (93% of
African origin)
1,552,970 (49.3%
black, 46.4%
white)
19942003, province
of Quebec, Canada
(37)
20082010 depending
on region, Mexico
City, Nuevo Leon,
Yucatan, Sinaloa,
Chihuahua, Mexico
(38)
20002009, island of
Barbados (39)
20022004, Atlanta,
GA, US (present
study)
COPCORD methodology
(community-based surveydirected physician
assessments)
NA
ND
ND
Incidence, per
100,000 per year
33 by PB, 33 by
HDD, 51
composite, 45
Bayesian model
60 overall, 80 in
females, 40 in
males, 90 in
Mexico City, 40
in Nuevo Leon,
70 in Yucatan,
40 in Sinaloa,
40 in
Chihuahua
84.1 overall, 152.6
in females, 10.1
in males
79 definite, 132
definite in
females, 25
definite in
males
Prevalence,
per 100,000
* SLE systemic lupus erythematosus; ACR American College of Rheumatology; ND not determined; ANA antinuclear antibody; NAN North American native;
NANN North American non-native; aPL antiphospholipid antibody; NHANES-III Third National Health and Nutrition Examination Survey; ICD-9 International
Classification of Diseases, Ninth Revision; PB physician billing; HDD hospital discharge data; COPCORD Community-Oriented Program for the Control of Rheumatic
Diseases; NA not available; VA Veterans Administration; USRDS US Renal Data System.
Age-adjusted to national or regional population.
Age- and sex-adjusted.
4 ACR 1982
criteria or
combined
definition by review
of charts and
laboratory data
4 ACR 1982
criteria
552,733 private
insured people
(race ND)
4 ACR 1982
criteria (definite)
or 13 ACR
criteria
(incomplete) by
chart review
ICD-9 code 710.0
19912001, rural
North Central
Wisconsin, US (35)
Case definition
Population at risk
(race/ethnicity)
(Contd)
Table 4.
366
LIM ET AL
367
to the data management and analysis, Wendy Carter for supervisory and administrative support, our team of medical abstractors (Patricia Jenkins, Levy Tong, Kamiran Jafar, Leisa
Rossello, Jessica McGann, Ara Alan, Sonya Belimesova, and
Marti Hand), Drs. Emily Somers and Joseph McCune and
colleagues from the University of Michigan, Ann Arbor, for
their collaboration, the Georgia Society of Rheumatology and
the Lupus Foundation of America for their support, and the
rheumatologists, nephrologists, dermatologists, and health systems for their participation.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Lim had full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Study conception and design. Lim, Helmick, Gordon, Drenkard.
Acquisition of data. Lim, Bayakly, Drenkard.
Analysis and interpretation of data. Lim, Helmick, Gordon, Easley,
Drenkard.
REFERENCES
1. Brunsting LA. Disseminated (systemic) lupus erythematosus. Proc
Staff Meet Mayo Clin 1952;27:4102.
2. Siegel M, Holley HL, Lee SL. Epidemiologic studies on systemic
lupus erythematosus: comparative data for New York City and
Jefferson County, Alabama, 1956-1965. Arthritis Rheum 1970;13:
80211.
3. Lim SS, Drenkard C, McCune WJ, Helmick CG, Gordon C,
DeGuire P, et al. Population-based lupus registries: advancing our
epidemiologic understanding. Arthritis Rheum 2009;61:14626.
4. Centers for Disease Control and Prevention. National Center for
Health Statistics. Bridged-race population estimates, United
States July 1st resident population by state, county, age, sex,
bridged-race, and Hispanic origin. Compiled from 1990-1999
bridged-race intercensal population estimates and 2000-2009 (Vintage 2009) bridged-race postcensal population estimates. URL:
http://wonder.cdc.gov/bridged-race-v2009.html.
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield
NF, et al. The 1982 revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum 1982;25:12717.
6. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating
the American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus [letter]. Arthritis
Rheum 1997;40:1725.
7. McCluskey R. Kidney pathology decennial: 1966-1975. In: Sommers S, editor. Lupus nephritis. New York: Appleton & Lange;
1975. p. 4569.
8. Weening JJ, DAgati VD, Schwartz MM, Seshan SV, Alpers CE,
Appel GB, et al, on behalf of the International Society of
Nephrology and Renal Pathology Society Working Group on the
Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited [published
erratum appears in J Am Soc Nephrol 2004;15:8356]. J Am Soc
Nephrol 2004;15:24150.
9. Weissleder R, Galarza DA, Garza MA. Lupus nephritis: classification, clinical features, and treatment. Rev Invest Clin 1987;39:
26376.
10. Costenbader KH, Karlson EW, Liang MH, Mandl LA. Defining
lupus cases for clinical studies: the Boston Weighted Criteria for
368
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
LIM ET AL
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic
lupus erythematosus. Arthritis Rheum 2012;64:267786.
Fessel WJ. Systemic lupus erythematosus in the community:
incidence, prevalence, outcome, and first symptoms; the high
prevalence in black women. Arch Intern Med 1974;134:102735.
Hochberg MC. The incidence of systemic lupus erythematosus in
Baltimore, Maryland, 19701977. Arthritis Rheum 1985;28:806.
Nossent JC. Systemic lupus erythematosus on the Caribbean
island of Curacao: an epidemiological investigation. Ann Rheum
Dis 1992;51:1197201.
Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, OFallon WM,
Gabriel SE. Trends in the incidence and mortality of systemic
lupus erythematosus, 19501992. Arthritis Rheum 1999;42:4650.
Peschken CA, Esdaile JM. Systemic lupus erythematosus in North
American Indians: a population based study. J Rheumatol 2000;
27:188491.
Walsh BT, Pope C, Reid M, Gall EP, Yocum DE, Clark LC. SLE
in a United States-Mexico border community. J Clin Rheumatol
2001;7:39.
Deligny C, Thomas L, Dubreuil F, Theodose C, Garsaud AM,
Numeric P, et al. Systemic lupus erythematosus in Martinique: an
epidemiologic study. Rev Med Interne 2002;23:219. In French.
Ward MM. Prevalence of physician-diagnosed systemic lupus
erythematosus in the United States: results from the Third National Health and Nutrition Examination Survey. J Womens
Health (Larchmt) 2004;13:7138.
Naleway AL, Davis ME, Greenlee RT, Wilson DA, McCarty DJ.
Epidemiology of systemic lupus erythematosus in rural Wisconsin.
Lupus 2005;14:8626.
Molina MJ, Mayor AM, Franco AE, Morell CA, Lopez MA, Vila
LM. Prevalence of systemic lupus erythematosus and associated
comorbidities in Puerto Rico. J Clin Rheumatol 2007;13:2024.
Bernatsky S, Joseph L, Pineau CA, Tamblyn R, Feldman DE,
Clarke AE. A population-based assessment of systemic lupus
erythematosus incidence and prevalenceresults and implications
of using administrative data for epidemiological studies. Rheumatology (Oxford) 2007;46:18148.
Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al, and the Grupo
de Estudio Epidemiologico de Enfermedades Musculo Articulares
(GEEMA). Epidemiology of the rheumatic diseases in Mexico: a
study of 5 regions based on the COPCORD methodology [published erratum appears in J Rheumatol Suppl 2011;38:585].
J Rheumatol Suppl 2011;86:38.
Flower C, Hennis AJ, Hambleton IR, Nicholson GD, Liang MH,
and the Barbados National Lupus Registry Group. Systemic lupus
erythematosus in an African Caribbean population: incidence,
clinical manifestations, and survival in the Barbados National
Lupus Registry. Arthritis Care Res (Hoboken) 2012;64:11518.